Ph.D.
Professor, School of Basic Medical Sciences, Fudan University
Research fellow, Cell and Gene Therapy Center, Fudan University Shanghai Cancer Center
Address: Rm. 1003, Bldg.13, 138 Yi XueYuan Rd, 200032 SHANGHAI
E-mail: haoyusun@fudan.edu.cn
Dr. Sun focuses on the discovery of immune checkpoints related to NK cell-based immunotherapy and their correlation with the tumor microenvironment. She has been granted with several fundings from National Science Foundation of China and National Key R&D Program of the Ministry of Science and Technology. She has published over 20 articles as first author and/or corresponding author in journals such as Science Advances, Nature Communications, Journal for ImmunoTherapy of Cancer, Journal of Hematology and Oncology, etc. She serves as an editorial member of Cellular & Molecular Immunology, Vice Chair of the Cell and Gene Therapy Committee of the China Pharmaceutical Innovation and Research Development Association, Vice Chair of the Gene and Cell Therapy Branch of the China Medicinal Biotechnology Association, Member of the Infection Immunology Branch of the Chinese Society of Immunology, and Council Member of the Shanghai Society for Immunology.
Research Interests: Tumor Immunology, NK cell, Immunotherapy
Publications:
Wang T, Xu Y, Zhang Z, Wu Y, Chen L, Zheng X, Peng H, Zou Q, Sun R, Ma H*, Sun H*, Tian Z*, Zheng X*. αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models. Nat Commun. 2025 Oct 17;16(1):9223.
Zhang Z, Zhang Y, Chen Y, Cao G, Zheng X, Sun R, Peng H, Tian Z*, Sun H*. CD200R blockade enhances anti-tumor immunity by unleashing NK and CD8+ T cells in tumor. Acta Pharmacol Sin. 2025 May 6;46(10):2835-2848.
Zhang Y, Li Y, Zhang Z, Zheng X, Peng H, Tian Z, Sun R*, Sun H*. CD49a targeting enhances NK cell function and antitumor immunity. Cancer Immunol Res. 2025 Jan 9;13(1):139-151.
Zhang C*, Wang H, Aji T, Li Z, Li Y, Ainiwaer A, Rousu Z, Li J, Wang M, Deng B, Duolikun A, Kang X, Zheng X, Yu Q, Shao Y, Zhang W, Vuitton DA, Tian Z, Sun H*, Wen H*. Targeting myeloid-derived suppressor cells promotes antiparasitic T-cell immunity and enhances the efficacy of PD-1 blockade. Nat Commun. 2024 Jul 27;15(1):6345.
Xiao X, Cheng Y, Zheng X, Fang Y, Zhang Y, Sun R, Tian Z*, Sun H*. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager. Front Immunol. 2023 Apr 11:14:1113303.
Bi J*, Jin X, Zheng C, Huang C, Zhong C, Zheng X, Tian Z*, Sun H*. Checkpoint TIPE2 Limits the Helper Functions of NK Cells in Supporting Antitumor CD8+ T Cells. Adv Sci (Weinh). 2023 Feb 19:e2207499.
Bi J*, Huang C, Jin X, Zheng C, Huang Y, Zheng X, Tian Z*, Sun H*. TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells. J Immunother Cancer. 2023 Feb;11(2):e006002.
Bi J*, Cheng C, Zheng C, Huang C, Zheng X, Wan X, Chen YH, Tian Z, Sun H*. TIPE2 is a checkpoint of natural killer cell maturation and antitumor immunity. Sci Adv. 2021;7(38):eabi6515.
Li YY, Zhang Y, Cao GS, Zheng XD, Sun C, Wei HM, Tian ZG, Xiao WH, Sun R*, Sun HY*. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors. J Hematol Oncol. 2021;14(1):100.
Cao GS, Cheng Y, Zheng XD, Wei HM, Tian ZG, Sun R*, Sun HY*. All-trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down-regulating B7-H6 expression via c-Myc signaling. Cancer Commun. 2021;41(1):51-61.